Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

The FDA said in a statement that it had determined that one of the two approved vaccines, Ixchiq (Valneva SE), which contains a live, weakened version of the chikungunya virus, was responsible for 21 ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

A detail of a packaging of the Ixchiq chikungunya vaccine, in a pharmacy in Saint-Denis, La Réunion, is shown March 21. The ...

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...

Hey, good morning. Today, we see CBER suspend the license for a chikungunya vaccine, look at a push to recall a safety and ...